146 related articles for article (PubMed ID: 33880619)
21. Glioblastoma: Vascular Habitats Detected at Preoperative Dynamic Susceptibility-weighted Contrast-enhanced Perfusion MR Imaging Predict Survival.
Juan-Albarracín J; Fuster-Garcia E; Pérez-Girbés A; Aparici-Robles F; Alberich-Bayarri Á; Revert-Ventura A; Martí-Bonmatí L; García-Gómez JM
Radiology; 2018 Jun; 287(3):944-954. PubMed ID: 29357274
[TBL] [Abstract][Full Text] [Related]
22. Comparison of Glioblastomas and Brain Metastases using Dynamic Contrast-Enhanced Perfusion MRI.
Jung BC; Arevalo-Perez J; Lyo JK; Holodny AI; Karimi S; Young RJ; Peck KK
J Neuroimaging; 2016; 26(2):240-6. PubMed ID: 26235208
[TBL] [Abstract][Full Text] [Related]
23. Differentiation Between True Tumor Progression of Glioblastoma and Pseudoprogression Using Diffusion-Weighted Imaging and Perfusion-Weighted Imaging: Systematic Review and Meta-analysis.
Tsakiris C; Siempis T; Alexiou GA; Zikou A; Sioka C; Voulgaris S; Argyropoulou MI
World Neurosurg; 2020 Dec; 144():e100-e109. PubMed ID: 32777397
[TBL] [Abstract][Full Text] [Related]
24. True progression versus pseudoprogression in the treatment of glioblastomas: a comparison study of normalized cerebral blood volume and apparent diffusion coefficient by histogram analysis.
Song YS; Choi SH; Park CK; Yi KS; Lee WJ; Yun TJ; Kim TM; Lee SH; Kim JH; Sohn CH; Park SH; Kim IH; Jahng GH; Chang KH
Korean J Radiol; 2013; 14(4):662-72. PubMed ID: 23901325
[TBL] [Abstract][Full Text] [Related]
25. Imaging biomarkers guided anti-angiogenic therapy for malignant gliomas.
Kong Z; Yan C; Zhu R; Wang J; Wang Y; Wang Y; Wang R; Feng F; Ma W
Neuroimage Clin; 2018; 20():51-60. PubMed ID: 30069427
[TBL] [Abstract][Full Text] [Related]
26. Differentiation of true progression from pseudoprogression in glioblastoma treated with radiation therapy and concomitant temozolomide: comparison study of standard and high-b-value diffusion-weighted imaging.
Chu HH; Choi SH; Ryoo I; Kim SC; Yeom JA; Shin H; Jung SC; Lee AL; Yoon TJ; Kim TM; Lee SH; Park CK; Kim JH; Sohn CH; Park SH; Kim IH
Radiology; 2013 Dec; 269(3):831-40. PubMed ID: 23771912
[TBL] [Abstract][Full Text] [Related]
27. Advanced imaging parameters improve the prediction of diffuse lower-grade gliomas subtype, IDH mutant with no 1p19q codeletion: added value to the T2/FLAIR mismatch sign.
Lee MK; Park JE; Jo Y; Park SY; Kim SJ; Kim HS
Eur Radiol; 2020 Feb; 30(2):844-854. PubMed ID: 31446467
[TBL] [Abstract][Full Text] [Related]
28. Identifying Voxels at Risk for Progression in Glioblastoma Based on Dosimetry, Physiologic and Metabolic MRI.
Anwar M; Molinaro AM; Morin O; Chang SM; Haas-Kogan DA; Nelson SJ; Lupo JM
Radiat Res; 2017 Sep; 188(3):303-313. PubMed ID: 28723274
[TBL] [Abstract][Full Text] [Related]
29. Primary central nervous system lymphoma and atypical glioblastoma: multiparametric differentiation by using diffusion-, perfusion-, and susceptibility-weighted MR imaging.
Kickingereder P; Wiestler B; Sahm F; Heiland S; Roethke M; Schlemmer HP; Wick W; Bendszus M; Radbruch A
Radiology; 2014 Sep; 272(3):843-50. PubMed ID: 24814181
[TBL] [Abstract][Full Text] [Related]
30. Vessel size and perfusion-derived vascular habitat refines prediction of treatment failure to bevacizumab in recurrent glioblastomas: validation in a prospective cohort.
Kim M; Park JE; Yoon SK; Kim N; Kim YH; Kim JH; Kim HS
Eur Radiol; 2023 Jun; 33(6):4475-4485. PubMed ID: 36242633
[TBL] [Abstract][Full Text] [Related]
31. Differentiating between Glioblastoma and Primary CNS Lymphoma Using Combined Whole-tumor Histogram Analysis of the Normalized Cerebral Blood Volume and the Apparent Diffusion Coefficient.
Bao S; Watanabe Y; Takahashi H; Tanaka H; Arisawa A; Matsuo C; Wu R; Fujimoto Y; Tomiyama N
Magn Reson Med Sci; 2019 Jan; 18(1):53-61. PubMed ID: 29848919
[TBL] [Abstract][Full Text] [Related]
32. Prediction of Core Signaling Pathway by Using Diffusion- and Perfusion-based MRI Radiomics and Next-generation Sequencing in Isocitrate Dehydrogenase Wild-type Glioblastoma.
Park JE; Kim HS; Park SY; Nam SJ; Chun SM; Jo Y; Kim JH
Radiology; 2020 Feb; 294(2):388-397. PubMed ID: 31845844
[TBL] [Abstract][Full Text] [Related]
33. Multiparametric MRI as a potential surrogate endpoint for decision-making in early treatment response following concurrent chemoradiotherapy in patients with newly diagnosed glioblastoma: a systematic review and meta-analysis.
Suh CH; Kim HS; Jung SC; Choi CG; Kim SJ
Eur Radiol; 2018 Jun; 28(6):2628-2638. PubMed ID: 29374321
[TBL] [Abstract][Full Text] [Related]
34. Quantitative Evaluation of Diffusion and Dynamic Contrast-Enhanced Magnetic Resonance Imaging for Differentiation Between Primary Central Nervous System Lymphoma and Glioblastoma.
Lu S; Wang S; Gao Q; Zhou M; Li Y; Cao P; Hong X; Shi H
J Comput Assist Tomogr; 2017; 41(6):898-903. PubMed ID: 28806317
[TBL] [Abstract][Full Text] [Related]
35. Integrative analysis of diffusion-weighted MRI and genomic data to inform treatment of glioblastoma.
Jajamovich GH; Valiathan CR; Cristescu R; Somayajula S
J Neurooncol; 2016 Sep; 129(2):289-300. PubMed ID: 27393347
[TBL] [Abstract][Full Text] [Related]
36. Multiparametric MRI for early identification of therapeutic response in recurrent glioblastoma treated with immune checkpoint inhibitors.
Song J; Kadaba P; Kravitz A; Hormigo A; Friedman J; Belani P; Hadjipanayis C; Ellingson BM; Nael K
Neuro Oncol; 2020 Nov; 22(11):1658-1666. PubMed ID: 32193547
[TBL] [Abstract][Full Text] [Related]
37. Developing a Pipeline for Multiparametric MRI-Guided Radiation Therapy: Initial Results from a Phase II Clinical Trial in Newly Diagnosed Glioblastoma.
Kim MM; Parmar HA; Aryal MP; Mayo CS; Balter JM; Lawrence TS; Cao Y
Tomography; 2019 Mar; 5(1):118-126. PubMed ID: 30854449
[TBL] [Abstract][Full Text] [Related]
38. Role of FDG-PET/MRI, FDG-PET/CT, and Dynamic Susceptibility Contrast Perfusion MRI in Differentiating Radiation Necrosis from Tumor Recurrence in Glioblastomas.
Hojjati M; Badve C; Garg V; Tatsuoka C; Rogers L; Sloan A; Faulhaber P; Ros PR; Wolansky LJ
J Neuroimaging; 2018 Jan; 28(1):118-125. PubMed ID: 28718993
[TBL] [Abstract][Full Text] [Related]
39. Spatial distribution of malignant tissue in gliomas: correlations of 11C-L-methionine positron emission tomography and perfusion- and diffusion-weighted magnetic resonance imaging.
Tietze A; Boldsen JK; Mouridsen K; Ribe L; Dyve S; Cortnum S; Østergaard L; Borghammer P
Acta Radiol; 2015 Sep; 56(9):1135-44. PubMed ID: 25270372
[TBL] [Abstract][Full Text] [Related]
40. Diffusion-weighted MRI of metastatic liver lesions: is there a difference between hypervascular and hypovascular metastases?
Schmid-Tannwald C; Thomas S; Ivancevic MK; Dahi F; Rist C; Sethi I; Oto A
Acta Radiol; 2014 Jun; 55(5):515-23. PubMed ID: 23986455
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
